ICON Public (NASDAQ:ICLR) Earns Outperform Rating from Leerink Partners

ICON Public (NASDAQ:ICLR)‘s stock had its “outperform” rating reissued by equities research analysts at Leerink Partners in a research note issued on Tuesday,Benzinga reports. They presently have a $255.00 price target on the medical research company’s stock, down from their prior price target of $270.00. Leerink Partners’ price target would indicate a potential upside of 25.20% from the stock’s current price.

Other equities research analysts have also issued research reports about the company. Evercore ISI lowered their price objective on ICON Public from $360.00 to $350.00 and set an “outperform” rating on the stock in a report on Tuesday, October 8th. Redburn Atlantic assumed coverage on ICON Public in a report on Monday, October 14th. They issued a “neutral” rating and a $311.00 price target for the company. TD Cowen decreased their target price on shares of ICON Public from $369.00 to $285.00 and set a “buy” rating on the stock in a research report on Friday, October 25th. Leerink Partnrs upgraded shares of ICON Public to a “strong-buy” rating in a report on Wednesday, September 18th. Finally, StockNews.com lowered ICON Public from a “buy” rating to a “hold” rating in a research report on Thursday, September 19th. Four research analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $292.45.

ICON Public Stock Performance

Shares of ICLR stock opened at $203.67 on Tuesday. The stock’s 50-day moving average price is $261.38 and its 200 day moving average price is $299.05. The company has a quick ratio of 1.34, a current ratio of 1.34 and a debt-to-equity ratio of 0.35. The stock has a market capitalization of $16.80 billion, a PE ratio of 22.71, a price-to-earnings-growth ratio of 1.40 and a beta of 1.25. ICON Public has a 52-week low of $183.38 and a 52-week high of $347.72.

ICON Public (NASDAQ:ICLR) last released its earnings results on Wednesday, October 23rd. The medical research company reported $3.35 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.72 by ($0.37). ICON Public had a net margin of 9.00% and a return on equity of 11.91%. The company had revenue of $2.03 billion during the quarter, compared to analyst estimates of $2.13 billion. During the same period in the previous year, the firm posted $3.10 EPS. The company’s revenue for the quarter was down 1.2% on a year-over-year basis. As a group, equities research analysts forecast that ICON Public will post 13.43 EPS for the current year.

Hedge Funds Weigh In On ICON Public

Hedge funds have recently bought and sold shares of the business. SkyView Investment Advisors LLC bought a new position in shares of ICON Public in the 1st quarter valued at approximately $1,021,000. EverSource Wealth Advisors LLC grew its stake in ICON Public by 17.4% in the 1st quarter. EverSource Wealth Advisors LLC now owns 283 shares of the medical research company’s stock valued at $95,000 after buying an additional 42 shares during the last quarter. GAMMA Investing LLC raised its holdings in ICON Public by 50.0% in the 2nd quarter. GAMMA Investing LLC now owns 261 shares of the medical research company’s stock worth $82,000 after acquiring an additional 87 shares during the period. ORG Partners LLC bought a new stake in ICON Public during the second quarter valued at about $59,000. Finally, Liontrust Investment Partners LLP grew its position in shares of ICON Public by 19.5% in the second quarter. Liontrust Investment Partners LLP now owns 119,728 shares of the medical research company’s stock valued at $37,531,000 after purchasing an additional 19,546 shares during the last quarter. 95.61% of the stock is owned by institutional investors and hedge funds.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.